Sugammadex ED90 dose to reverse the rocuronium neuromuscular blockade in obese patients

Dose ED90 de Sugamadex para reverter o bloqueio neuromuscular com rocurônio em pacientes obesos

MAURO PRADO DA SILVAA; CHRISTIANO MATUSI; DANIEL DONGIOU KIM; JOAQUIM EDSON VEIRAX; CARLOS ALBERTO MALHEIROS; LIGIA ANDRADE SILVA TELLES MATHIASS.

INTRODUCTION

The pathophysiological changes determined by obesity can affect the distribution and elimination of medications1,2. The majority of drugs with high lipid solubility have a high distribution volume3. Measures of weight correction to indicate the best scheme of drug administration in obese patients have been proposed4-6. A simple and easy method of calculating ideal body weight (IBW) considers height in centimeters (cm) minus 100 for men and height in centimeters less 110 for women7.

Sugammadex, a selective binding agent that reverses rocuronium-induced neuromuscular blockade (NMB), can be rapidly distributed into the extracellular fluid, which should therefore be considered as its distribution volume (DV)8. This substance is used in adults of normal weight at 2mg/kg to promote reversal of moderate NMB, measured by the train-of-four (TOF) stimulus sequence (T4/T1 ≥ 0.9); at 4mg/kg for reversal of deep NMB; and at a dose of 16mg/kg for immediate reversal of rocuronium-induced NMB9-13.

Results in patients with grade III obesity submitted to laparoscopic bariatric surgery under NMB indicated an optimal dose of 2mg/kg of sugammadex based on 140% of the IBW for patients with moderate neuromuscular blockade14. However, a prospective observational study found that 23.4% of patients required a second dose of sugammadex to reverse moderate NMB over a two-minute time interval when a dose of 2mg/kg was used in comparison with the time of reversion between non-obese subjects15.

There are sequential evaluation methods for binary response variables used to determine the concentration or dose associated with the 50% point of the dose-response curve. The up-and-down method is commonly used in anesthesia research16. Briefly, the first patient with a positive response to the received dose will indicate an initial lower subsequent dose to the next patient; if the patient does not have a positive response, the next will receive a higher dose. This procedure is repeated until the end of the determined experiment17.

ABSTRACT

Objective: to determine the ED90 (minimum effective dose in 90% of patients) of sugammadex for the reversal of rocuronium-induced moderate neuromuscular blockade (NMB) in patients with grade III obesity undergoing bariatric surgery. Methods: we conducted a prospective study with the biased coin up-and-down sequential design. We chosen the following doses: 2.0mg/Kg, 2.2mg/Kg, 2.4mg/Kg, 2.6mg/Kg, 2.8mg/Kg. The complete reversal of rocuronium-induced NMB considered a T4/T1 ratio ≥ 0.9 as measured by TOF. After induction of general anesthesia and calibration of the peripheral nerve stimulator and accelerometer, we injected rocuronium 0.6mg/kg. We administered propofol and remifentanil by continuous infusion, and intermittent boluses of rocuronium throughout the procedure. Results: we evaluated 31 patients, of whom 26 had displayed successful reversal of the NMB with sugammadex, and failure in five. The mean time to complete moderate NMB reversal was 213 seconds (172-300, median 25-75%). The ED90 of sugammadex calculated by regression was 2.39mg/kg, with a 95% confidence interval of 2.27-2.46 mg/kg. Conclusion: the ED90 of sugammadex in patients with grade III obesity or higher was 2.39mg/kg.

Keywords: Dose-Response Relationship, Drug. Obesity. Cyclodextrins.
Previous studies have suggested that reversal of NMB in morbidly obese patients could be achieved at 4mg/kg for deep blockade considering the ideal body weight, or 2mg/kg, regardless of which body weight is considered, ideal or actual\textsuperscript{18,19}.

The aim of this study was to determine the minimum effective dose of sugammadex in 90\% of obese patients (ED 90) required to complete the reversal of rocuronium-induced moderate neuromuscular blockade using the up-and-down design of biased coin (BCD) in patients with grade III obesity submitted to bariatric surgery. We also recorded the mean time to NMB reversal in these patients with obesity grade III or higher.

**METHODS**

We conducted a prospective study using the biased coin up-and-down sequential method (BCD) to determine the ED90 of patients with obesity grade III or higher undergoing bariatric surgery receiving sugammadex for the reversal of moderate neuromuscular blockade induced by rocuronium. We studied patients operated at the Central Hospital of the Brotherhood of the São Paulo Holy Home of Mercy, from January to October 2013. The estimated sample size considered 20 patients to determine the lowest effective dose\textsuperscript{18}.

Inclusion criteria were patients older than 18 years and under 60 years, body mass index ≥ 40 kg/m\textsuperscript{2}, with indication of bariatric surgery and who signed the informed consent term. We did not include Patients with a history of neuromuscular disease, use of medicinal products that could interfere with neuromuscular transmission, allergy to aminosteroid-class neuromuscular blocking agents, any anticipated difficulties in managing the airways, or renal failure.

We chose the doses of sugammadex to reach the decile 0.9: 2.0mg/kg; 2.2mg/kg; 2.4mg/kg; 2.6mg/kg; 2.8mg/kg, and also considering patients’ IBW. The first patient in the study received a dose of 2.4mg/kg and, if there was a negative response, the next patient would be considered to receive a next higher dose of 2.6mg/kg. However, in the case where 2.4mg/kg produced a positive response, the next patient would be randomized with a 10\% probability of receiving the next dose of 2.2mg/kg and 90\% probability of receiving the same dose of 2.4mg/kg. We repeated this procedure subsequently until the end of the study\textsuperscript{17}.

Complete NMB reversal occurred when the patient had a TOF T4/T1 ratio ≥ 0.9 within eight minutes of sugammadex infusion at the prescribed dose. In case of failure, the same dose was repeated until complete neuromuscular blockade reversal.

The anesthesia technique included denitrogenation with 100\% oxygen in proclivity position, followed by intravenous (IV) infusion of fentanyl 5µg/kg IBW and propofol 2mg/kg total body weight. Soon after calibration of the peripheral nerve stimulator and accelerometer, we injected rocuronium IV at the dose of 0.6mg/kg of IBW.

### Table 1. Anthropometric data and procedures times (median, 25-75\%).

<table>
<thead>
<tr>
<th></th>
<th>Successes (n=26)</th>
<th>Failures (n=5)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (years)</strong></td>
<td>42 (35-45)</td>
<td>45 (40-52)</td>
</tr>
<tr>
<td><strong>Height (m)</strong></td>
<td>1.62 (1.55-1.73)</td>
<td>1.59 (1.59-1.67)</td>
</tr>
<tr>
<td><strong>Weight (kg)</strong></td>
<td>126.5 (110-149)</td>
<td>130 (124-130)</td>
</tr>
<tr>
<td><strong>BMI (kg/cm\textsuperscript{2})</strong></td>
<td>49.3 (44.3-52.0)</td>
<td>46.7 (46.6-51.4)</td>
</tr>
<tr>
<td><strong>Time of surgery (min)</strong></td>
<td>194.5 (158.5-223.7)</td>
<td>220 (203.0-225.0)</td>
</tr>
<tr>
<td><strong>Anesthesia time (min)</strong></td>
<td>240 (206-295)</td>
<td>300 (270-305)</td>
</tr>
<tr>
<td><strong>Time to awake (min)</strong></td>
<td>10.5 (7.2-15.7)</td>
<td>12 (10.0-20.0)</td>
</tr>
<tr>
<td><strong>Rocuronium total dose (mg)</strong></td>
<td>96 (84.2-117.8)</td>
<td>100 (79.2-119.4)</td>
</tr>
<tr>
<td><strong>Sugammadex total dose (mg)</strong></td>
<td>123.6 (108-160.8)</td>
<td>117.6 (107.8-136.8)</td>
</tr>
</tbody>
</table>

BMI: body mass index.
to NMB. We maintained anesthesia with propofol 2 to 6 mg/kg/h to keep the bispectral index (BIS) at 40 to 60, remifentanil 0.1 to 0.3 µg/kg/h and intermittent boluses of rocuronium at 0.3µg/kg of IBW, still adjusted to maintain a maximum of only two responses, T1 and T2, in TOF. Patients were referred to a stay of no less than six hour in the post-anesthetic recovery unit (PACU), in which the neuromuscular function was clinically evaluated by the TOF, both on admission and on discharge from the unit.

Patients were monitored with cardioscope, pulse oximetry, capnography (in ventilation to maintain ETCO\textsubscript{2} between 35 and 40 mmHg), noninvasive blood pressure, central temperature (forced warm air blanket maintained in the upper body), BIS, TOF (Electrodes on the ulnar nerve and accelerometer on the thumb). The four-stimulus sequence was monitored every five minutes after calibration of the monitor for each patient, and immediately after the infusion of sugammadex at 15-second intervals until T4/T1 ≥0.9 (TOFWatch SX, Organon Ltd Dublin, Ireland).

We used the statistical software R version 3.0.2 (R Foundations for Statistical Computing, Vienna, Austria), as well as the Sigma Stat statistical package for Windows version 2.03 (SPSS Inc., Chicago, IL, USA). We used the isotonic regression functions with the pooled-adjacent-violators algorithm (PAVA) to determine the ED90, and bootstrapping to calculate the respective 95% confidence interval with the statistical program R\textsuperscript{17-19}.

This study was approved by the Ethics in Research Committee of the Brotherhood of the São Paulo Holy Home of Mercy and was registered at ClinicalTrials.gov under the number: NCT02568345.

**RESULTS**

The ED90 of sugammadex calculated by isotonic regression was 2.39mg/kg, with a 95% confidence interval of 2.27-2.46 mg/kg, calculated by the bootstrapping method with 9,999 replicates of the sample. There were no patients with residual neuromuscular blockade at any of the three time points studied after complete reversal of moderate NMB with sugammadex.

Thirty-one patients completed the study, 24 females (77%) and seven males (23%). Anthropometric data and procedure times (median, 25 to 75%) did not differ between groups (Table 1). Twenty-six patients achieved complete reversal of moderate neuromuscular blockade with sugammadex (77% female), and five patients failed to achieve it (80% female), and the time for reversal was smaller with the higher dose (Figure 1, Table 2).

**DISCUSSION**

This study establishes the effective ED90 dose of sugammadex at 2.39mg/kg (95% CI: 2.27-2.46 mg/kg) for the reversal of rocuronium-induced moderate neuromuscular blockade in obese patients ≥ grade III. The biased coin design (BCD) allowed the use of small samples, reducing the time of execution and also the number of individuals tested with ineffective doses, which is interesting from an ethical point of view.

![Figure 1](image-url). Up-and-down sequence of the biased coin for administered doses (n=31). Empty circle: failure to reverse the lockade; Full circle: complete reversal of the blockade.

<table>
<thead>
<tr>
<th>Dose (mg/kg)</th>
<th>Success</th>
<th>Subjects studied</th>
<th>Observed probability</th>
<th>PAVA-adjusted probability</th>
<th>Time to reversion (s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.20</td>
<td>0</td>
<td>3</td>
<td>0.0</td>
<td>0.0</td>
<td>-</td>
</tr>
<tr>
<td>2.40</td>
<td>23</td>
<td>25</td>
<td>0.92</td>
<td>0.92</td>
<td>213 (172-300)</td>
</tr>
<tr>
<td>2.60</td>
<td>3</td>
<td>3</td>
<td>1.0</td>
<td>1.0</td>
<td>150 (150-229)</td>
</tr>
</tbody>
</table>

**PAVA:** pooled-adjacent-violators algorithm.
In the classical up-and-down model, the doses tested are concentrated closer to the 0.5 decile (ED50), but the estimated probabilistic dose with higher efficiency should be situated close to decile 0.9 (ED90). However, the efficiency of this procedure is disputed by some authors. Most studies with this approach in anesthesiology study 20-40 patients.

A recent study did not point out the total dose of rocuronium, while other investigations point to an average of 97.5mg of rocuronium for 120 minutes of surgery duration. The present study observed individuals who had the moderate neuromuscular blockage successfully reversed after receiving 100.8mg of rocuronium for 194 minutes of surgery duration. An additional variable that could be difficult to compare relates to the definition of ideal body weight, since we did not base our study on expected tables for height and weight. Nevertheless, our results confirm recent investigations suggesting sugammadex doses in a range of 2-4 mg/kg of ideal body weight.

Some limitations of this study are the lack of investigation for the minimal effective dose in other clinically relevant situations, such as during superficial or deep neuromuscular blockade in individuals with obesity ≥ grade III. Additional studies may examine these variables.

In conclusion, for obese grade III or higher, the ED90 dose for sugammadex to reverse rocuronium-induced neuromuscular blockade was 2.39mg/kg within a mean infusion time of 213 seconds.

REFERENCES


RESUMO

Objetivos: determinar a ED90 (dose mínima eficaz em 90% dos pacientes) de sugamadex para a reversão de bloqueio neuromuscular (BNM) moderado induzido pelo rocurônio em pacientes com obesidade grau III submetidos à cirurgia bariátrica. Métodos: estudo prospectivo com o método de projeção sequencial para cima e para baixo da moeda enviada. As seguintes doses foram escolhidas: 2,0mg/kg, 2,2mg/kg, 2,4mg/kg, 2,6mg/kg, 2,8mg/kg. A reversão completa de BNM induzido por rocurônio considerou uma relação T4/T1 ≥ 0,9 na medida do TOF. Após a indução da anestesia geral e calibração do estimulador de nervo periférico e acelerômetro, rocurônio 0,6mg/kg foi injetado. Infusão contínua de propofol e remifentanil, e bolus intermitente de rocurônio foram injetados durante todo o procedimento. Resultados: trinta e um pacientes foram avaliados, 26 dos quais bem-sucedidos e cinco sem reversão completa do BNM moderado promovido pelo sugamadex. O tempo médio para completar reversão de BNM foi 213 segundos (172 a 300 segundos; mediana, 25-75%). O ED90 de sugamadex calculado pela regressão foi de 2,39mg/kg com um intervalo de confiança de 95% (2,27 a 2,46mg/kg).

Conclusão: o ED90 de sugamadex em pacientes com obesidade grau III ou superior foi 2,39mg/kg.


Received in: 22/09/2016
Accepted for publication: 11/10/2016
Conflict of interest: none.
Source of funding: none.

Mailing address:
Joaquim Edson Vieira
E-mail: joaquimev@usp.br
joaquim.vieira@fm.usp.br